Thirty women presenting for major gynaecological oncology surgery under a standardized, combined epidural/general anaesthetic technique received either placebo or tenoxicam 20 mg intravenously, in a randomized double-blinded manner prior to surgery. Plasma and urinary electrolytes, creatinine, prostaglandins PgE 2 and PgF1α, and thromboxane (T x B 2 ) were collected 12 hours preoperatively and then for four days postoperatively.
SUMMARY Thirty women presenting for major gynaecological oncology surgery under a standardized, combined epidural/general anaesthetic technique received either placebo or tenoxicam 20 mg intravenously, in a randomized double-blinded manner prior to surgery. Plasma and urinary electrolytes, creatinine, prostaglandins PgE 2 and PgF1α, and thromboxane (T x B 2 ) were collected 12 hours preoperatively and then for four days postoperatively.
There were no significant differences in any of the measured parameters between the groups, at any of the measurement times. Mean (SD) creatinine clearance at baseline, 24 h and 48 h was 100.4 (29.7) and 86. 9 (27.5) , 128. 1 (45.9) and 115.0 (40.3), 137. 5 (50.7) and 121. 6 (38.6) in the placebo and tenoxicam groups respectively (P=0.28). Both groups required similar amounts of intraoperative ephedrine and intravenous fluids to maintain blood pressure. The minimal changes in plasma and renal parameters reflect predictable responses to major surgery and rehydration rather than any response to cyclooxygenase inhibition. This may underscore the importance of maintenance of blood pressure during the course of surgery and postoperative care, and perhaps the usefulness of a fluid loading regimen to preserve renal function during surgery.
The predicted attenuation of renal prostaglandin-mediated protective mechanisms and enhancement of the catecholamine-mediated renal vasoconstriction by the use of a single 20 mg dose of tenoxicam in this study were not seen. Modulation of renal concentrating mechanisms or excretion of sodium and potassium by tenoxicam was not apparent and a large increase in study size would be required to detect a significant difference in these parameters as a consequence of the drug, over and above any changes in response to surgery and epidural anaesthesia.
Keywords: NSAID: tenoxicam, prostanoid, epidural, renal function All nonsteroidal anti-inflammatory drugs (NSAIDs) have a variable capacity to inhibit cyclooxygenase (COX) and thereby block the biosynthesis of renal prostaglandins 1 . Cyclooxygenase may exist as two isoforms, COX-1 which is constitutive and is protective in the stomach and kidneys, and COX-2, which is induced by inflammatory stimuli in joints and various cells 2 . In theory, NSAIDs that selectively inhibit COX-2 without any inhibition of COX-1 should have anti-inflammatory activity without gastrointestinal and renal toxic effects 3 . All NSAIDs currently available in Australia block both COX-1 and COX-2, but there are differences in their relative selectivity for the two isoenzymes 2 . Tenoxicam has an intermediatory IC 50 COX-2/COX-1 ratio but the application of different test systems to measure COX selectivity has resulted in controversy and confusion 4 .
Renal prostaglandins are mainly vasodilators which do not play a major role in normal subjects where the basal rate of synthesis is relatively low. However, prostacyclin and prostaglandin E 2 release is enhanced by underlying renal disease, by hypercalcaemia and by angiotensin II and noradrenaline 5 . Increased secretion of these hormones is a feature of states of effective volume depletion including true volume depletion, cirrhosis and cardiac failure 5 . Under these conditions, vasodilator prostaglandins act to preserve renal blood flow. NSAIDs are therefore potentially nephrotoxic 6 , particularly in patients with compromised renal function and the elderly where significant renal impairment is often present despite a normal plasma creatinine concentration 7 . There have been relatively few reports of renal function following contemporary anaesthesia employing these agents for pain relief 8,9 . This study is designed to test whether a single preoperative IV dose of tenoxicam 20 mg affects renal function in the acute postoperative phase in an elderly population undergoing major surgery and subjected to a renal protection strategy.
MATERIALS AND METHODS
Thirty patients, aged 50 to 70 years, undergoing laparotomy for ovarian, uterine or cervical cancer were enrolled prospectively to participate in a study, approved by the Royal Women's Hospital Ethics Committee. Each patient received a verbal and plain language written description of the research protocol and all gave written consent. Patients unable to give a valid consent, or who had renal or hepatic impairment (defined for this study as any routinely measured preoperative biochemical value which fell outside the normal range published by our laboratory), bleeding diathesis, hypersensitivity to NSAIDs, asthma or requiring medication known to interfere with tenoxicam disposition were excluded. Roche Pharmaceuticals coded and randomized 30 patients using random number tables to receive either tenoxicam 20 mg diluted in 2 ml or normal saline 2 ml with vitamin B complex as colouring (prepared by Roche Pharmaceuticals (Basle, Switzerland)). The tenoxicam allocation code was not released until the end of clinical data collection and therefore all investigators, pain assessment anaesthetists, nurses and surgeons were blinded to treatment. There were no exclusions from the original data set.
Renal Protection Strategy
On the day prior to surgery clinical chemistry and urinary prostaglandin and thromboxane were measured. Four hours before the anticipated surgery, urine collection was initiated after insertion of an indwelling urinary catheter and an IV infusion of 0.9% saline (10 ml.kg -1 ) was commenced via a 16 gauge cannula inserted into the cephalic vein to complete in 60 minutes and then slowed to a rate which maintained IV patency until the start of surgery. Two hours prior to the commencement of surgery, a 23 gauge radial arterial cannula was inserted with local anaesthetic infiltration and blood samples for predrug renal chemistry were obtained. Temazepam 0.2 mg.kg -1 was administered orally, followed by intravenous administration of the blinded preparation via the cephalic vein cannula.
Anaesthesia
During surgery the patient was monitored using the Datex AS3 system (Datex Instrumentarium Corp, Helsinki, Finland). Direct arterial blood pressure, electrocardiograph, and pulse oximetry monitoring were established before induction of anaesthesia. Fentanyl 1 µg.kg -1 and midazolam 0.02 mg.kg -1 were given IV 60 seconds prior to the commencement of induction of anaesthesia with propofol 2 mg.kg -1 . Vecuronium 0.1 mg.kg -1 was administered to facilitate tracheal intubation and mechanical ventilation. Patients were ventilated to obtain an end-tidal carbon dioxide level of 35 mmHg and anaesthesia was maintained with isoflurane 1% in nitrous oxide and oxygen 35%. After general anaesthesia was induced, the patient was turned to the left lateral position and an epidural catheter placed via an 18 gauge Tuohy needle at the thoracic 11-12 interspace and advanced 5 cm inside the epidural space. Two 5 ml bolus doses of an epidural solution containing fentanyl 2 µg.ml -1 in plain bupivacaine 0.125% were administered five minutes apart, followed by a continuous infusion of the same solution at 8 ml.h -1 (IMED Gemini PC-1, San Diego, California). Crystalloid and colloid were administered together with 3 mg to 6 mg bolus doses of ephedrine to maintain mean arterial pressure within 20% of baseline values and packed cells were given intraoperatively when blood loss exceeded 10% of estimated blood volume (70 ml.kg -1 ). At the end of the operative procedure muscle relaxation was reversed with neostigmine and atropine.
Renal Function
Urine was collected preoperatively for the 12-hour period prior to urinary catheter insertion and for the 2-hour period after the intravenous volume load to measure baseline creatinine clearance as a marker for glomerular filtration rate (GFR). Twenty-four hour urine collections were continued postoperatively for four days for estimation of urinary electrolytes, urea and creatinine. Blood samples were taken at the commencement of each urine collection period for estimation of plasma electrolytes, creatinine, urea, protein, bilirubin, gamma glutaryl transferase (GGT) and alkaline phosphatase (ALP). Clearances were calculated using the standard formula UV/Pt, where U is the urine concentration, V urine volume, P plasma concentration and t time. Fractional sodium and potassium excretion were calculated using the formula (U.PCr)/(P.UCr). Electrolyte free water reabsorption (TeC H2O ) was calculated using the formula V[(U Na +U K )/P Na -1].
Renal Eicosanoid Analysis
pH-adjusted (3.5) urinary samples were stored in quadruplicate 10 ml aliquots at -70°C in polypropylene tubes until analysis. Samples were thawed to room temperature for analysis and pH adjusted to less than 3.5 if necessary by the addition of glacial acetic acid or 6M hydrochloric acid. To each 500 µl urine sample, 50 µl of diluted 3 H prostaglandin was added plus 2 ml 100% ethanol. Each sample was then allowed to stand at 4°C for five minutes before centrifugation at 2700 rpm for 10 minutes to precipitate proteins. The supernatant was decanted into a 10 ml polypropylene tube to which 8 ml 0.1M sodium phosphate buffer (pH 7.2) was added. Sep Pak Vac C18 columns were activated with 5 ml 100% ethanol, then washed with deionized water. Each prepared 10 ml sample was added to the C18 column and eluted under gravity with 3 ml of 1% methanol in ethylacetate. The solvent was evaporated to dryness and reconstituted with 1ml buffer. A 500 µl aliquot of this sample underwent scintillation counting and the remainder was subjected to enzyme immunoassay (EIA). Reconstituted prostaglandin F1α diluted from the bulk standard (5 ng/ml) into 500, 250, 125, 62.5, 31.3, 15.6, 7.8, and 3.9 µl concentrations. Then 50 µl of the standard or sample were added to the precoated EIA plate, followed by the PgF1α anticholinesterase tracer and the PgF1α antiserum. The plate was covered with plastic film and incubated for 18 hours at 4°C, followed by development with Ellman's reagent in the dark for 90 to 120 minutes and then read at 412 nm on an EIA plate reader. Similar enzyme immunoassays were undertaken to determine PgE 2 and thromboxane (T x B 2 ) levels using appropriate reconstituted concentrations and plate development times.
Statistical Analysis
A 50% difference in glomerular filtration rate between the tenoxicam (50 ml/min) and placebo groups (100±45 ml/min) would be clinically significant. With 
RESULTS
The patients in each group were comparable in age, height, weight, triceps skin fold, type and duration of surgery and ASA status ( Table 1 ). There were no withdrawals and no early code breakers. Table 2 shows that there were no differences between the groups in fluid volumes administered to maintain perfusion and urine flow.
Renal function appeared unchanged by this surgical experience with GFR remaining stable in both groups despite the impact of anaesthesia and surgery (Table 3 ). Fractional excretion of sodium and potassium declined minimally at 48 hours postoperatively along with the plasma sodium concentration, while urine output and osmolar clearance remained constant over the 96-hour period ( Table 3) .
Free water clearance decreased to a minimum in the first 24 hours postoperatively and then increased progressively as volume was replaced. Similarly, electrolyte-free water reabsorption increased to maximal values in the first 24 hours postoperatively and then decreased to negative values over the next 48 hours, partly explaining the transient increase in urinary electrolyte concentrations over the same time period. There were no significant differences between the groups at any of the measurement times. Urine and plasma electrolyte concentrations changed minimally from baseline values and remained within normal limits (Figures 1 and 2) .
Two hours after administration of the trial drug there was an identical small decline in PgE 2 levels in both the tenoxicam and placebo groups, with T levels virtually unchanged from baseline (Figure 3 ). Plasma eicosanoid levels responded to surgery in a predictable manner with a slight rise in both prostaglandins and thromboxane during the first postoperative day but a relatively small fall in the renal eicosanoid ratio during the first 24 hours, which consequently returned to baseline values on the fourth postoperative day. There were no adverse events reported related to tenoxicam.
DISCUSSION
Administration of a single intravenous dose of tenoxicam 20 mg two hours prior to surgery caused insignificant alterations in the measured indices of renal function in elderly women undergoing major gynaecological surgery. The minimal changes in plasma and renal parameters reflect predictable responses to major surgery and rehydration resulting in transient vasopressin inhibition, rather than any response to cyclooxygenase inhibition 5 . This may underscore the importance of maintenance of blood pressure during the course of surgery and postoperative care, and perhaps the usefulness of a fluid loading regimen to preserve renal function during surgery 10 . The latter may have obscured any effect of tenoxicam on renal eicosanoid levels, although the preoperative renal and vascular status of the patient are critical predictors of the response to inhibition of prostaglandin synthesis 1 . De Lasson and colleagues, investigating a possible renal protective role for felodipine, also showed that when renal and central haemodynamics are kept relatively constant during surgery, the changes in renal parameters from normal values are insignificant 11 . A significant decrease in renal function can be expected if prolonged hypotension is deliberately induced, but renal function rapidly returns to normal values when normotension is resumed 12 .
Slaven and colleagues demonstrated a 60% decrease in GFR immediately postoperatively with a concurrent elevation in arginine vasopressin (AVP) levels and a decline in free water clearance (C H2O ) over the subsequent six hours 13 . This occurred despite preoperative fluid loading in patients undergoing elective laminectomy and was thought to be due to a physiological response to stress resulting in the observed increase in tubular reabsorption and AVP secretion. However, as these and other authors correctly point out, the degree of impact on renal performance will also depend on the type of anaesthetic administered and the surgical procedure 14 . In animal studies epidural anaesthesia results in a functional "denervation" of the kidney such that renal blood flow no longer reflects cardiac output and plasma renin levels do not correspond to the degree of vascular resistance 15 . AVP and renal blood flow were not measured during this study but the minimal change in GFR, water clearance and urine volume might suggest that amelioration of surgical stress by pre-incisional epidural insertion resulted in preservation of renal function during the early postoperative phase. Similar data have also been reported by Brinkmann and colleagues studying the effect of ibuprofen on renal function in patients undergoing infrarenal aortic surgery under thoracolumbar epidural anaesthesia 16 .
The predicted attenuation of renal prostaglandinmediated protective mechanisms and enhancement of the catecholamine-mediated renal vasoconstriction 17 by the use of a single 20 mg dose of tenoxicam in this study did not materialize. Whether this resulted from the mode of drug administration, the renal protection strategy, the preoperative renal and fluid status of the patients or pre-emptive epidural analgesia reducing the effect of endogenous vasoconstrictor release on renal blood flow was not determined. This could not be accounted for by a difference between the groups in exogenous fluid and ephedrine administration 18 .
Patients with overt renal disease were excluded from this study and therefore conclusions drawn should be guarded in relation to other patient cohorts, however it appears that IV tenoxicam administration to elderly patients with "normal" renal function undergoing major surgery does not produce clinically significant adverse effects on renal function. There were no differences between the placebo and study group at any of the measurement times and although IV tenoxicam 20 mg has a half-life of approximately three days 19 , its impact on endogenous renal eicosanoid synthesis appears minimal. Exercise, salt restriction and/or dehydration cause transient reductions in renal function that may be buffered by vasodilatory prostaglandins 20 . There was no inter-group difference in the ratio between vasodilative (PgE 2 and PgF1α) and vasoconstrictive (T x B 2 ) renal prostanoids inferring that any COX-1 blockage attributable to tenoxicam may have been counterbalanced by concurrent inhibition of TxB 2 21 . A modulation of renal concentrating mechanisms or excretion of sodium and potassium by tenoxicam was not apparent. The small difference (6%) in GFR detected between the tenoxicam and placebo groups was not statistically significant. Power analysis suggests a sample size of 65 in each group would
